Gene therapy patients monitored for years to ensure lasting safety and relief
NCT ID NCT06262399
Summary
This study is monitoring people who previously received an investigational gene therapy called NTLA-2002 for hereditary angioedema (HAE). The main goal is to track their long-term health, safety, and how well the treatment continues to control their HAE attacks over time. It is an observational study, meaning participants are not receiving new treatment but are being followed to gather important long-term data.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital
Cambridge, United Kingdom
-
Campbelltown Hospital
Campbelltown, New South Wales, 2560, Australia
-
Centre National de Reference - Grenoble
Grenoble, France
-
Charite-Universitätsmedizin Berlin
Berlin, 12203, Germany
-
Hôpital Claude Huriez
Lille, 59037, France
-
New Zealand Clinical Research
Auckland, New Zealand
-
University of Amsterdam Academic Medical Center
Amsterdam, Netherlands
Conditions
Explore the condition pages connected to this study.